North Wales, PA, United States of America

Catherine Julia Pachuk

This inventor holds 22 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Gene Silencing Techniques. Top assignees: Alnylam Pharmaceuticals, Inc., American Home Products Corporation, Nucleonics, Inc.. Active years: 1999-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catherine Julia Pachuk. Retrieved from https://idiyas.com/inventor/catherine-julia-pachuk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 11)

% Patents Active = 68.2

CIPO Patents = 3

EPO Patents = 11 (Patent Applications = 6)

Average Co-Inventor Count = 2.5

ph-index = 9

Forward Citations = 304(Granted Patents)

Location History:

North Wales, PA (US) (2001)
Lansdowne, PA (US) (2000 - 2004)
Blue Bill, PA (US) (2011)
Lansdale, PA (US) (1999 - 2015)
Northborough, MA (US) (2013 - 2015)
Cambridge, MA (US) (2013 - 2021)

Company Filing History:

12 out of 466

Alnylam Pharmaceuticals, Inc.

patents

6 out of 1,567

American Home Products Corporation

The General Hospital Corporation

6. 1 out of 834,513

Other

patents

Years Active: 1999-2021

Loading Chart...

Areas of Expertise:

HCV Sequences

HBV Sequences

Gene Silencing

RNA Interference

dsRNA Delivery

Hepatitis C Vaccine

Transfection Kinetics

Ribozymes

DNA Vaccines

Vesicular Complexes

Expression Constructs

Cloning Methods

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10982212 - Conserved HBV and HCV sequences useful for gene silencing (2021-04-20),

2. 9982263 - Conserved HBV and HCV sequences useful for gene silencing (2018-05-29),

3. 9200281 - Conserved HBV and HCV sequences useful for gene silencing (2015-12-01),

4. 9198927 - Targeting opposite strand replication intermediates of single-stranded viruses by RNAI (2015-12-01),

5. 9051566 - Post-transcriptional gene silencing using expressed double stranded RNA (2015-06-09),

6. 8987227 - Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use (2015-03-24),

7. 8614198 - Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use (2013-12-24),

8. 8575327 - Conserved HBV and HCV sequences useful for gene silencing (2013-11-05),

9. 8524679 - In vivo delivery of double stranded RNA to a target cell (2013-09-03),

10. 8350021 - Conserved HBV and HCV sequences useful for gene silencing (2013-01-08),

11. 8299042 - Methods and compositions for silencing genes without inducing toxicity (2012-10-30),

12. 7985581 - Multiple RNA polymerase III promoter expression constructs (2011-07-26),

13. 7897382 - Transfection kinetics and structural promoters (2011-03-01),

14. 7527945 - Transfection kinetics and structural promoters (2009-05-05),

15. 6831169 - Hepatitis C virus vaccine (2004-12-14),

Title: **Catherine Julia Pachuk: Innovator in Gene Silencing Technologies**

Introduction

Catherine Julia Pachuk, located in North Wales, PA, has made significant contributions to the field of biotechnology with her impressive portfolio of 22 patents. Her innovative work focuses primarily on gene silencing technologies aimed at combatting viral infections, particularly those caused by hepatitis B and C viruses.

Latest Patents

Among her latest patents is a groundbreaking invention that includes conserved HBV and HCV sequences useful for gene silencing. These conserved consensus sequences derived from known strains of hepatitis B and C viruses are designed to inhibit the expression of these viruses in mammalian cells. This advancement provides therapeutic utility against HBV and HCV infections in humans by effectively silencing the genes responsible for these viral pathogens.

Career Highlights

Catherine has built her career working with leading companies in the pharmaceutical sector, including Alnylam Pharmaceuticals and American Home Products Corporation. Her research and development efforts within these organizations have paved the way for new therapeutic strategies to address viral infections, emphasizing her role as a key innovator in the industry.

Collaborations

Throughout her career, Catherine has collaborated with notable individuals, including Chandrasekhar Satishchandran and Vincent R. Zurawski. These partnerships have enriched her research endeavors and contributed to the advancement of innovative solutions in the realm of gene therapy.

Conclusion

Catherine Julia Pachuk stands out as a prominent inventor in the field of biotechnology, particularly through her work on gene silencing and therapeutic approaches to viral infections. Her extensive patent portfolio and collaborations reflect her commitment to innovation and her pivotal role in advancing medical science.

Profile summary based on public USPTO records.